WO2014109587A1 - 천연 추출물을 포함하는 당뇨합병증 또는 혈관부종의 예방 또는 치료용 약학적 조성물 및 건강기능식품 조성물 - Google Patents
천연 추출물을 포함하는 당뇨합병증 또는 혈관부종의 예방 또는 치료용 약학적 조성물 및 건강기능식품 조성물 Download PDFInfo
- Publication number
- WO2014109587A1 WO2014109587A1 PCT/KR2014/000292 KR2014000292W WO2014109587A1 WO 2014109587 A1 WO2014109587 A1 WO 2014109587A1 KR 2014000292 W KR2014000292 W KR 2014000292W WO 2014109587 A1 WO2014109587 A1 WO 2014109587A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- diabetic
- coph
- extract
- composition
- rhubarb
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 83
- 208000002249 Diabetes Complications Diseases 0.000 title claims abstract description 26
- 206010012655 Diabetic complications Diseases 0.000 title claims abstract description 24
- 235000013376 functional food Nutrition 0.000 title claims abstract description 12
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 11
- 239000000203 mixture Substances 0.000 claims abstract description 60
- 244000078534 Vaccinium myrtillus Species 0.000 claims abstract description 35
- 235000017537 Vaccinium myrtillus Nutrition 0.000 claims abstract description 35
- 244000194101 Ginkgo biloba Species 0.000 claims abstract description 18
- 235000003095 Vaccinium corymbosum Nutrition 0.000 claims abstract description 12
- 235000021014 blueberries Nutrition 0.000 claims abstract description 12
- 239000004480 active ingredient Substances 0.000 claims abstract description 11
- 206010012601 diabetes mellitus Diseases 0.000 claims description 64
- 241000219061 Rheum Species 0.000 claims description 46
- 235000009411 Rheum rhabarbarum Nutrition 0.000 claims description 46
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 27
- 208000028185 Angioedema Diseases 0.000 claims description 17
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 17
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 15
- 238000000605 extraction Methods 0.000 claims description 14
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- 229940087603 grape seed extract Drugs 0.000 claims description 11
- 235000002532 grape seed extract Nutrition 0.000 claims description 11
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 11
- 229960003105 metformin Drugs 0.000 claims description 11
- 239000001717 vitis vinifera seed extract Substances 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 230000036541 health Effects 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 7
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 6
- 230000006872 improvement Effects 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 5
- 208000010837 Diabetic eye disease Diseases 0.000 claims description 4
- 206010046996 Varicose vein Diseases 0.000 claims description 4
- 206010007749 Cataract diabetic Diseases 0.000 claims description 3
- 208000001344 Macular Edema Diseases 0.000 claims description 3
- 206010025415 Macular oedema Diseases 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 208000001132 Osteoporosis Diseases 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 201000007025 diabetic cataract Diseases 0.000 claims description 3
- 208000019622 heart disease Diseases 0.000 claims description 3
- 201000010230 macular retinal edema Diseases 0.000 claims description 3
- 239000012046 mixed solvent Substances 0.000 claims description 3
- 238000002137 ultrasound extraction Methods 0.000 claims description 2
- 238000003809 water extraction Methods 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 208000038015 macular disease Diseases 0.000 claims 1
- 235000009754 Vitis X bourquina Nutrition 0.000 abstract description 5
- 235000012333 Vitis X labruscana Nutrition 0.000 abstract description 5
- 240000006365 Vitis vinifera Species 0.000 abstract description 5
- 235000014787 Vitis vinifera Nutrition 0.000 abstract description 5
- 241000037740 Coptis chinensis Species 0.000 abstract description 3
- 244000201986 Cassia tora Species 0.000 abstract description 2
- 235000014552 Cassia tora Nutrition 0.000 abstract description 2
- 241000219780 Pueraria Species 0.000 abstract description 2
- 244000046146 Pueraria lobata Species 0.000 abstract description 2
- 240000001745 Rheum palmatum Species 0.000 abstract description 2
- 235000008090 Rheum palmatum Nutrition 0.000 abstract description 2
- 240000008669 Hedera helix Species 0.000 abstract 2
- 244000277285 Cassia obtusifolia Species 0.000 abstract 1
- 235000006719 Cassia obtusifolia Nutrition 0.000 abstract 1
- 241001618264 Rubus coreanus Species 0.000 abstract 1
- 241000208341 Hedera Species 0.000 description 40
- 230000002401 inhibitory effect Effects 0.000 description 35
- 238000010171 animal model Methods 0.000 description 22
- 238000004519 manufacturing process Methods 0.000 description 21
- 238000004458 analytical method Methods 0.000 description 16
- 210000004204 blood vessel Anatomy 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 14
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 14
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 14
- 210000004155 blood-retinal barrier Anatomy 0.000 description 13
- 230000004378 blood-retinal barrier Effects 0.000 description 13
- 230000005764 inhibitory process Effects 0.000 description 13
- 230000002207 retinal effect Effects 0.000 description 13
- 210000001525 retina Anatomy 0.000 description 12
- 230000006378 damage Effects 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 230000001419 dependent effect Effects 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 238000004445 quantitative analysis Methods 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 229920002307 Dextran Polymers 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 230000036252 glycation Effects 0.000 description 8
- 230000002792 vascular Effects 0.000 description 8
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 7
- 244000265736 Nelumbo pentapetala Species 0.000 description 7
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 7
- 229940087559 grape seed Drugs 0.000 description 7
- 239000011593 sulfur Substances 0.000 description 7
- 229910052717 sulfur Inorganic materials 0.000 description 7
- 235000019209 bilberry extract Nutrition 0.000 description 6
- 229940102480 bilberry extract Drugs 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 238000004451 qualitative analysis Methods 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 241000252212 Danio rerio Species 0.000 description 5
- 235000011201 Ginkgo Nutrition 0.000 description 5
- 102000000424 Matrix Metalloproteinase 2 Human genes 0.000 description 5
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 210000005240 left ventricle Anatomy 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 210000001210 retinal vessel Anatomy 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- HCAJQHYUCKICQH-VPENINKCSA-N 8-Oxo-7,8-dihydro-2'-deoxyguanosine Chemical compound C1=2NC(N)=NC(=O)C=2NC(=O)N1[C@H]1C[C@H](O)[C@@H](CO)O1 HCAJQHYUCKICQH-VPENINKCSA-N 0.000 description 4
- 201000004569 Blindness Diseases 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000007795 chemical reaction product Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 201000001421 hyperglycemia Diseases 0.000 description 4
- 230000007830 nerve conduction Effects 0.000 description 4
- 210000001328 optic nerve Anatomy 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 3
- 239000009429 Ginkgo biloba extract Substances 0.000 description 3
- 102000003940 Occludin Human genes 0.000 description 3
- 108090000304 Occludin Proteins 0.000 description 3
- 206010038848 Retinal detachment Diseases 0.000 description 3
- 230000003178 anti-diabetic effect Effects 0.000 description 3
- 239000003472 antidiabetic agent Substances 0.000 description 3
- 239000012223 aqueous fraction Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 239000002034 butanolic fraction Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000002257 embryonic structure Anatomy 0.000 description 3
- 239000002778 food additive Substances 0.000 description 3
- 235000013373 food additive Nutrition 0.000 description 3
- 208000017169 kidney disease Diseases 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 208000027185 varicose disease Diseases 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 206010063547 Diabetic macroangiopathy Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 208000003790 Foot Ulcer Diseases 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 208000018262 Peripheral vascular disease Diseases 0.000 description 2
- 206010057430 Retinal injury Diseases 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 241000219793 Trifolium Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 238000013532 laser treatment Methods 0.000 description 2
- 210000001365 lymphatic vessel Anatomy 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 201000001474 proteinuria Diseases 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000013042 tunel staining Methods 0.000 description 2
- GIANIJCPTPUNBA-QMMMGPOBSA-N (2s)-3-(4-hydroxyphenyl)-2-nitramidopropanoic acid Chemical compound [O-][N+](=O)N[C@H](C(=O)O)CC1=CC=C(O)C=C1 GIANIJCPTPUNBA-QMMMGPOBSA-N 0.000 description 1
- UBDZFAGVPPMTIT-UHFFFAOYSA-N 2-aminoguanidine;hydron;chloride Chemical compound [Cl-].NC(N)=N[NH3+] UBDZFAGVPPMTIT-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 244000045231 Canavalia maritima Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 244000147568 Laurus nobilis Species 0.000 description 1
- 235000017858 Laurus nobilis Nutrition 0.000 description 1
- 206010025282 Lymphoedema Diseases 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000731396 Pueraria montana var. thomsonii Species 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 101000808006 Rattus norvegicus Vascular endothelial growth factor A Proteins 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 102100035604 Synaptopodin Human genes 0.000 description 1
- 101710119889 Synaptopodin Proteins 0.000 description 1
- 235000005212 Terminalia tomentosa Nutrition 0.000 description 1
- 102000000591 Tight Junction Proteins Human genes 0.000 description 1
- 108010002321 Tight Junction Proteins Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 235000012511 Vaccinium Nutrition 0.000 description 1
- 241000736767 Vaccinium Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011697 diabetes animal model Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000001497 fibrovascular Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 229940068052 ginkgo biloba extract Drugs 0.000 description 1
- 235000020686 ginkgo biloba extract Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 208000002502 lymphedema Diseases 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 206010062198 microangiopathy Diseases 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 210000003668 pericyte Anatomy 0.000 description 1
- 208000030613 peripheral artery disease Diseases 0.000 description 1
- 230000003836 peripheral circulation Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 210000003994 retinal ganglion cell Anatomy 0.000 description 1
- 210000001957 retinal vein Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 230000003966 vascular damage Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to a pharmaceutical composition and health functional food composition for preventing or treating diabetic complications or angioedema comprising ivy leaf and rhubarb mixed extract as an active ingredient, more specifically rhubarb, brown root It relates to a pharmaceutical composition and health functional food composition for preventing or treating diabetic complications or angioedema further comprising, as an active ingredient, ginkgo biloba, bladder, blueberry, bilberry, bokbunja or grape seed extract.
- Diabetes is one of the world's most common adult diseases, with the prevalence of diabetes reaching 10% in Korea, and the current number of diabetics exceeding 240 million people worldwide.In 2025, the number increased to 380 million worldwide. In 2009, 60 percent of the cases in Asia were reported by the American Medical Association (JAMA). In particular, the onset of diabetes mellitus was brought to the young and the elderly, and as the lifespan was extended, complications could not be avoided.
- JAMA American Medical Association
- Diabetic retinopathy occurs more than 60% within 10 years of onset of diabetes and more than 90% within 20 years. In Korea, the cost of diabetic complications in peripheral circulation increased from 87.7 billion won in 2006 to 1553 billion won in 2010, and diabetic retinopathy increased 54.4% from 32 billion won to 50.5 billion won. Diabetic retinopathy is a microangiopathy caused by chronic diabetes, which is characterized by permeability changes in retinal vessels, vascular obstruction, ischemia, neovascularization, and thus fibrovascular proliferation. It features. Diabetic retinopathy is the leading cause of blindness in adults, with 12,000 to 24,000 people dying from diabetes in the United States each year. In spite of laser treatment or vitreous surgery, 8% reported blindness without progression. Therefore, early detection, suppression of progression, and early treatment of diabetic retinopathy are required, but the etiology is not yet accurately identified, and effective treatment is limited.
- Diabetic neuropathy develops in more than 80% of diabetic patients and is caused by the accumulation of metabolic by-products, the loss of myelin and neurovascular changes in neurons. Treatment of neurosis is generally not easy and prevention of symptoms such as blood sugar control and relief of pain such as pain are being made.
- Peripheral vascular disease is found in 45% of patients after about 20 years of diabetes mellitus. vascular hardening and blood circulation disorders are common symptoms, and complete healing is difficult. For example, foot ulcers are a serious complication that result in amputation of the limbs.
- Diabetic nephropathy due to chronic diabetes does not function properly due to hemodialysis, and then suddenly proceeds to the stage of kidney transplantation.
- Chronic diabetes causes blood vessels and lymphatic vessels to malfunction, resulting in leakage or stagnation of tissue fluid and blood.
- this symptom appears in the blood vessels of the retina, macular edema and macular degeneration due to abnormal changes such as drusen, varicose veins appear in the veins, lymph edema appear in the lymphatic vessels, and varicose veins appear in the lower extremities.
- This is accompanied by vision impairment, blindness, restless leg pain, pain, paresthesia, and nocturnal pain.
- there is no medicament and it is being administered at the antioxidant level (4 editions of Diabetes Research, Korean Diabetes Association, Korea Medicine, 2011, p. 577).
- Treatments for macular degeneration include expensive intravascular endothelial growth factor therapy or laser treatment, but are not cured and still require fatal vision disorders.
- Nonenzymatic glycation of protein refers to the formation of advanced glycation endproducts (AGEs) by condensation reactions (millard reactions) of amino acid groups such as lysine residues of proteins and reducing sugars without enzymatic action. Reaction. Unlike reversible amido-type early glycosylated end glycosylated products, the final glycosylated product is an irreversible reaction product. Once produced, blood sugar is not degraded even after recovery to normal, but accumulates in tissues during protein survival, resulting in abnormal tissue structure and function.
- Changes in the body cause complications such as diabetic retinopathy, diabetic cataract, diabetic nephropathy, diabetic neuropathy, diabetic cancer, diabetic heart disease, diabetic osteoporosis, foot ulcers or diabetic arteriosclerosis (Vinson , JA et al., 1996, J. Nutritional Biochemistry 7: 559-663; Smith, PR et al., 1992, Eur. J. Biochem., 210: 729-739).
- the inventors have prepared a composition comprising an ivy leaf and rhubarb mixed extract as an active ingredient, or an extract of rhubarb, brown root, ginkgo biloba, clover, blueberry, bilberry, bokbunja or grape seed extract to the ivy leaf and rhubarb mixed extract. It was confirmed that the composition has excellent efficacy in preventing or treating diabetic complications and angioedema, such as inhibition of final glycation end product production, inhibition of endothelial growth factor production, inhibition of retinal blood barrier and optic nerve collapse, improvement of nerve conduction, improvement of nephropathy, and foot ulceration.
- the invention has been completed.
- An object of the present invention is to provide a pharmaceutical composition and health functional food composition comprising a mixture of ivy leaf and sulfur extract as an active ingredient that can prevent or treat diabetic complications or angioedema.
- the mixed extract of the ivy leaf and the yellow lotus of the present invention exhibits blood retinal barrier damage inhibitory activity, vascular endothelial growth factor inhibitory activity, and excellent activity of inhibiting the production of the final glycation product, which is an indicator of diabetic complications, diabetic complications or angioedema It is effective in the prevention or treatment of, and can be usefully used as a component of medicines or functional foods derived from natural products that have no side effects on the human body.
- 1 is a result of inhibiting the enlarged vitreoretinal blood vessels of the zebrafish model of the mixture of ivy leaf extract and sulfur extract (COPH).
- Figure 2 shows the results of (a) qualitative analysis and (b) quantitative analysis of inhibition of vascular retinal damage of COPH in STZ-diabetic animal model.
- FIG. 3 shows the results of (a) proteinuria, (b) final glycation end products (AGEs) and (c) 8-OHdG in the STZ-diabetic animal model.
- 5 is a serum albumin outflow effect of retinal blood vessels in a diabetic animal model of COPH or COPH + MET.
- Figure 6 shows the results of inhibiting the loss of dense seam protein (occludin) in the retina of the diabetic animal model of COPH or COPH + MET.
- MMP2 matrix proteinase
- Figure 8 shows the results of (a) qualitative analysis and (b) quantitative analysis of the inhibitory effect of the end glycated product production in the retinal vessels of COPH or COPH + MET in diabetic animal model.
- VEGF retinal vascular endothelial factor
- Figure 10 shows the results of (a) qualitative analysis and (b) quantitative analysis of the retinal acellular capillary production inhibitory efficacy of COPH or COPH + MET in diabetic animal model.
- Figure 11 shows the results of inhibition of retinal neuronal cell damage of COPH or COPH + MET in diabetic animal model.
- FIG. 13 is a diagram showing the results of improvement of motor nerve conduction (MNCV) of COPH (FIG. 13A and 13B) and myelein degeneration in a diabetic animal model (FIG. 13C).
- MNCV motor nerve conduction
- Figure 14 shows the results of (a) qualitative analysis and (b) quantitative analysis of retinal vascular damage inhibition effect of COPH in a diabetic animal model.
- the present invention provides a pharmaceutical composition for the prevention or treatment of diabetic complications or angioedema comprising a mixed extract of ivy leaf and rhubarb as an active ingredient.
- composition may further include rhubarb, rhubarb, ginkgo biloba, Cultivator, blueberry, bilberry, bokbunja or grape seed extract in the mixed extract of ivy leaf and rhubarb.
- Mated extract of ivy leaf and rhubarb means an extract prepared by extracting a mixture of ivy leaf and rhubarb extract, or a mixture of ivy leaf and rhubarb.
- Ivy lobe is known to alleviate neuralgia, rheumatism.
- Ivy leaf extract is preferably prepared by extracting with water, methanol, ethanol, butanol or a mixed solvent, but is not limited thereto.
- Rhubarb extract is preferably prepared by extracting with water, methanol, ethanol, butanol or a mixed solvent, but is not limited thereto.
- Rheum palmatum is a healthy, relieving agent known to be good for habitual constipation.
- the "root” is Pueraria thynbergiana ( P. lobata , P. thomsonii ) and is used for indigestion, abdominal pain, colds and bleeding.
- Ginkgo (Ginkgo leaf) is a function, such as antioxidant activity.
- Clark is a seed of Cassia tora , C. obtusifolia , and has an effect of lowering blood pressure and lowering cholesterol.
- Blueberry ( Vaccinium spp ., Blueberry) has functions such as antioxidant activity, anti-ulcer and anti-inflammatory action, intestinal action.
- “Bilberry” has functions such as protecting eyesight and lowering cholesterol.
- Billbunja includes anti-inflammatory, antioxidant, anti-Helicobacter pylori action.
- the rhubarb, rhubarb, ginkgo biloba leaves, blueberry, bilberry, bokbunja or grape seed extract is extracted by rhubarb, brown root, ginkgo biloba leaves, blueberry, bilberry, bokbunja or grape seed with water, methanol, ethanol, butanol or a mixture thereof It is preferred to be prepared, but is not limited thereto.
- metformin metalformin
- the composition in addition to the ivy leaf extract and sulfur extract.
- metformin is added, the effect of the composition is significantly increased.
- Metformin is preferably added 1 to 7 times the total weight of the mixed extract of the ivy leaf and the yellow lotus.
- the extraction is preferably at room temperature extraction, hot water extraction, cold needle extraction, reflux cooling extraction, ultrasonic extraction, supercritical or steam extraction, but is not limited thereto.
- the ivy leaf extract may comprise a fraction of the ivy leaf extract.
- fraction means a specific component obtained by suspending the ivy leaf extract in water and then sequentially dividing with a solvent having a different polarity.
- the solvent may be ethyl acetate, n-butanol or water.
- the fraction of the ivy leaf extract may be obtained by suspending the ivy leaf ethanol extract in water and fractionating with ethyl acetate, the water fraction obtained by suspending in water and fractionating with ethyl acetate, butanol obtained by fractionation with butanol Fractions or water fractions.
- the ivy leaf ethanol extract may be a butanol fraction or a water fraction obtained by suspending in water and then fractionated with butanol.
- Diabetes complications means the symptoms caused when diabetes lasts for a long time. Diabetes complications differ from the onset criteria and judgment criteria of diabetes mellitus, and a diabetic complication treatment agent is used separately from a diabetes treatment agent. Diabetic complications include diabetic eye disease, diabetic retinopathy, diabetic cataract, diabetic nephropathy, diabetic neuropathy, diabetic cancer, diabetic heart disease, diabetic osteoporosis, diabetic arteriosclerosis, coronary artery disease, Peripheral vascular diseases caused by diabetes, such as peripheral artery disease, cerebrovascular disease, and the like.
- Angioedema refers to a condition in which the permeability of blood vessels deep in the skin, beneath the skin, or under the mucosa increases, causing fluid to escape from the blood vessels and build up in surrounding tissues.
- angioedema include varicose veins, macular edema or macular lesions.
- a composition containing an extract of a mixture of ivy and rhubarb extracts or extracts of ivy and rhubarb extracts is further mixed with rhubarb, brown root, ginkgo biloba leaf, blueberry, bilberry, bokbunja or grape seed extract is diabetic complications or angioedema It was confirmed that it is effective in the prevention or treatment of.
- a mixed composition prepared by adding grape seed, ginkgo biloba, roots, bladder, rhubarb or bilberry extract to the mixed extract of the ivy leaf extract and the yellow lotus is 2 to 10 times higher than aminoguanidine which is a positive control.
- the mixed extract of the ivy leaf and the yellow leaf extract prevents diabetic complications or angioedema by confirming the effects of inhibiting blood retinal barrier damage, inhibiting endothelial growth factor production, inhibiting acellular capillary formation, improving motor neuron conduction and improving nephropathy. It was confirmed that there was a therapeutic effect.
- composition of the present invention may include a pharmaceutically acceptable carrier, excipient or diluent in addition to the above-described active ingredient for administration.
- compositions of the present invention can be used in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, or the like, oral preparations, suppositories, or sterile injectable solutions, respectively, according to conventional methods.
- composition of the present invention can be administered orally or parenterally (eg, applied intravenously, subcutaneously, intraperitoneally or topically) according to the desired method, and the dosage is based on the condition and weight of the patient, the extent of the disease, Depending on the drug form, route of administration, and time, it may be appropriately selected by those skilled in the art.
- the daily dosage of the mixed extract of the ivy leaf and the yellow lotus is preferably 1 mg / kg to 1500 mg / kg, and may be administered once to several times daily if necessary.
- the present invention also provides a method for preventing or treating diabetic complications or angioedema comprising administering the composition to a subject in need thereof.
- composition, diabetic complications and angioedema are as described above.
- the present invention also provides a health functional food composition for the prevention or improvement of diabetic complications or angioedema comprising a mixed extract of ivy leaf and rhubarb as an active ingredient.
- composition of the present invention preferably further comprises rhubarb, rhubarb, ginkgo biloba, Cultivator, blueberry, bilberry, bokbunja or grape seed extract in the mixture of ivy leaf and yellow lotus.
- the health functional food may further include food additives, and the suitability as a "food additive" is in accordance with the General Regulations and General Test Act of the Food Additives Code approved by the Food and Drug Administration unless otherwise specified Determined by the relevant standards and standards.
- the ivy leaf extract and the yellow lotus extract according to the present invention added to the food containing the beverage in the process of manufacturing a health functional food can be appropriately added or subtracted as needed, preferably 1 weight to 100% by weight of food It is preferred to add from 15% to 15% by weight.
- Example 1 Preparation of a composition comprising an ivy leaf extract and a sulfur extract
- the ivy leaf extract and the yellow lotus extract obtained by the above method were mixed in a weight ratio of 3: 1 to prepare a sample COPH.
- each natural medicinal extract extract composition 15 seeds of each natural medicinal extract extract composition were prepared by mixing grape seed, ginkgo biloba, brown root, bladder, rhubarb or bilberry extract with a certain ratio to COPH prepared in Example 1.
- Dry grape seed extract was used as Enteron ® of Hallym Pharmaceuticals. Samples of COPH + Grape Seed 1 (1: 1), COPH + Grape Seed 2 (2: 1) and COPH + Grape Seed 3 (3: 1) were prepared by mixing grape seed extract with COPH at a weight ratio of 1: 1, 1: 2 or 1: 3. It was.
- Ginkgo biloba extract was used SKIN Chemical's Ginexin-F ® .
- Ginkgo leaf extract was mixed with COPH in a weight ratio of 1: 3 to prepare a sample COPH + ginkgo leaf (3: 1).
- the dried roots were concentrated under reduced pressure by primary and secondary extraction and filtration with an aqueous 80% (v / v) ethanol solution.
- Samples of dry coarse root extracts were mixed with COPH in a weight ratio of 1: 1 or 1: 3 to prepare COPH + brown root 1 (1: 1) and COPH + brown root 2 (3: 1).
- the dry crystals were concentrated by primary, secondary extraction, filtration and reduced pressure with an aqueous 80% (v / v) ethanol solution.
- the dry crystal extracts were mixed with COPH in a weight ratio of 1: 1, 1: 2 or 1: 3 to prepare sample COPH + clarifier1 (1: 1), COPH + clarifier2 (2: 1) and COPH + clarifier3 (3: 1). Prepared.
- Dry bilberry extract was used Tage-F ® of the international drug.
- the bilberry extract was mixed with COPH in a weight ratio of 1: 1, 1: 2, 1: 3 or 3: 1, and the sample COPH + bilberry 1 (1: 1), COPH + bilberry 2 (2: 1), COPH + bilberry 3 (3: 1) and COPH + bilberry 4 (1: 3) were prepared.
- Sample COPH + MET was prepared by adding 350 parts by weight of metformin to 50 parts by weight of the ivy leaf extract and the sulfur extract extract composition (COPH).
- Bovine serum albumin (BSA), a protein source, was mixed and prepared in a phosphate buffer solution.
- the sugar source was a mixture of 0.2M fructose and 0.2M glucose.
- Each of the compositions prepared in Examples 1 and 2 and each of aminoguanidine (positive control) were added to a mixture of bovine serum albumin and sugar and incubated for 7 days. After incubation, the resulting final glycation product was analyzed. The amount of the final glycosylated product was calculated by the following equation (1) using a microplate reader (Excitation; 350 nm, Emission; 450 nm).
- the mixed composition prepared by adding grape seed, ginkgo biloba, brown root, clover, rhubarb or bilberry extract to COPH also showed an excellent inhibitory effect on the production of final glycosylated product from 2 to up to 10 times as compared to aminoguanidine, a positive control group.
- zebrafish embryos were used to verify the inhibitory effect of the expansion of the vitreous vascular diameter.
- Transgenic zebrafish Tg (kdr: EGFP) embryos expressing fluorescent proteins in vascular endothelial cells were induced with high blood sugar (30 mm glucose).
- Retinal detachment was performed in 8 rats randomly for 3 weeks and analyzed for retinal vessel leakage. After anesthesia, 5 minutes after injection of fluorescein-dextran and consciousnessest 33342 into the left ventricle of the heart, the eye was removed and the retina was detached. The detached retina was mounted and observed under a fluorescence microscope. For quantitative analysis, after injection of fluorescein-dextran into the left ventricle, cardiac blood was collected and perfused to remove residual fluorescein-dextran, and the eyes were extracted to separate retinas. The separated retina was homogenized and only the supernatant was measured for FITC-dextran by spectrophotometer.
- the protein concentration was quantified by the Bio-Rad kit (Bio-Rad Laboratories Inc, USA) by the Bradford method.
- the amount of Albumin in urine, the amount of final glycated product (AGEs), the amount of 8-OHdG and the amount of synaptopodin as oxidative stress indicators were measured by ELISA (FIG. 3).
- the diabetic group (DM) increased significantly compared to the normal group (NOR) in all three renal function indicators after 6 weeks of diabetic induction.
- the COPH-administered group decreased significantly in a concentration dependent manner. This means that COPH is effective in preventing diabetic nephropathy.
- the normal group (NOR) has no fluorescence leakage phenomenon, but the diabetic group (DM) has a leakage of blood from the blood vessels due to damage of the blood retinal barrier in most individuals. It was bright.
- metformin-treated group (MET) showed a decrease in fluorescence leakage and brightness compared to diabetic group (DM).
- the brightness was decreased due to the fluorescence leakage in a concentration-dependent manner, and especially in the high concentration COPH-administered group, the fluorescence leakage was significantly reduced.
- COPH + MET mixed administration group showed the best inhibitory effect. This means that synergy between COPH and metformin is great.
- Immunohistochemical staining assay confirmed the effect of inhibiting intercellular compact protein damage, matrixase inhibitory expression, final glycation end product accumulation and vascular endothelial growth factor inhibitory effect (Figs. 6 to 9).
- the diabetic group has broken the thread-like connection of occludin in the various blood vessels (arrow). However, the occludin loss was prevented (treated) in the COPH and COPH + MET groups.
- MMP2 matrix metalloproteinase-2
- the diabetic group increased the expression of MMP2 (arrow), COPH administered group and COPH + MET mixed group was suppressed MMP2 expression.
- the diabetic group (DM) produced about twice as much final glycated product as compared to the normal (NOR), but the COPH-administered group and the COPH + MET mixed-administered group were significantly inhibited.
- VEGF vascular endothelial growth factor
- VEGF induces new angiogenesis and increases blood vessel permeability. It also induces the production of matrix proteins. Therefore, it was confirmed whether the vascular permeability inhibitory effect of the COPH and COPH + MET administration group is due to the inhibition of the production of vascular endothelial production factor (Fig. 9).
- the diabetic group significantly increased the production of VEGF in the retinal tissues, and the expression of VEGF was significantly suppressed in the COPH, MET, and COPH + MET mixed groups.
- retinopathy One of the earliest symptoms of diabetic retinopathy is that the nuclei of pericyte, a peripheral cell caused by acellular capillary formation, die and progress to retinopathy.
- the retina was removed and washed in the eye and then cultured. Internal membrane was removed from digested retina. The vascular frame was observed in the cell wall and nucleus after separation and drying in the retinal background (Fig. 10).
- the diabetic group (DM) increased acellular capillaries by about five times, whereas the COPH-administered group and the COPH + MET mixed-administered group were significantly anemic. Formed capillaries were inhibited.
- optic nerve loss One of the causes of blindness in diabetic retinopathy is optic nerve loss.
- hyperglycemia causes optic nerve loss due to sandpaper death. Therefore, retinal optic nerve death was confirmed by TUNEL staining assay which can confirm cell death using retinal sections (FIG. 11).
- the diabetic group showed strong fluorescence (arrow) in the nucleus of retinal ganglion cells, but the COPH and COPH + MET mixed administration groups suppressed neuronal cell death in a concentration-dependent manner.
- ROS Free radicals
- RNS free radicals
- these two indicators were strongly expressed in the diabetic group (DM), but the COPH-administered group decreased expression in a concentration-dependent manner, and the COPH high-dose group and the COPH + MET mixed group were very effective in inhibiting expression.
- mice with blood glucose levels of 350 mg / dl or higher were selected and the samples were orally administered once daily for 6 weeks.
- Experimental groups are normal (NOR), diabetic (DM), COPH 25 mg / kg / day administration group (COPH-25) and COPH 50 mg / kg / day administration group (COPH-50).
- mice were anesthetized, fixed on a warm plate, and measured in the paranasal nerve with a neuroconductor (AD Intrument, Australia). At the tail start point, the precipitating pole gave electric stimulation and recorded the action potential.
- the active electrode and the control electrode were spaced 1 cm apart. The measurement was performed at a stimulation time of 0.1 msec, a filtration frequency of 10 Hz to 10 kHz, a recording sensitivity of 5 mV / div, and a recording speed of 1 ms / div. The average value was calculated by measuring a total of 10 times (FIG. 13).
- the diabetic group (DM) was reduced in nerve conduction rate compared to the normal group (NOR) 6 weeks after the induction of diabetes.
- the COPH-administered group improved the decrease in nerve conduction rate in a concentration-dependent manner, and the COPH-50-administered group showed a significant improvement.
- the efficacy was analyzed five times a week, two weeks, three weeks, six weeks, and 12 weeks after administration.
- test group included (1) normal (NOR), (2) diabetic (DM), (3) COHP 25 mg / kg (CHOP-25) administration group, and (4) COHP 50 mg / kg (DCHOP-50) administration group. to be.
- the drug was administered orally once a day, and the efficacy of each parking lot was checked for 1, 2, 3, 6, 12 weeks, and 5 times in total.
- H & E staining and PAS staining were used to observe the pathological and morphological changes of the tissues.
- SDS-PAGE electrophoresis was performed after protein quantification using the Lowry principle. The amount of protein was measured by the scion image analysis program (density).
- the fluorescence outflow phenomenon due to blood retinal barrier damage was analyzed every 1, 2, 3, 6, 12 weeks.
- Diabetic group (DM) significantly increased fluorescence leakage from 2 weeks after the start of the experiment.
- COHP-25 and CHOP-50 administration groups significantly inhibited the outflow of fluorescence from 3 weeks.
- Rat VEGF protein (Vascular endothelial growth factor, R & D research, USA) was injected into the left eye of 7-year-old male SD rats to induce blood retinal wall disruption.
- the amount of intraocular vitreous in rats is approximately 50-55 ⁇ l, 12 ⁇ g / ml, 60 ⁇ g / ml and 120 ⁇ g / ml of the drug were administered 12 times higher than the final intraocular concentration.
- each rat was anesthetized to secure a heart and injected with fluorescein-dextran in the left ventricle.
- the eye was removed and for the left eye the retina was detached from the eyecup.
- the detached retina was mounted and dried for observation.
- fluorescein-dextran was injected into the left ventricle, blood was collected, and fluorescein-dextran was removed from the blood vessels. After centrifugation of the separated retina, the supernatant was measured for fluorescence with an ELISA reader (FIG. 15).
- the normal group did not have a fluorescence leakage phenomenon
- the VEGF intraocular administration group observed that all the phosphors leak out of the blood vessels.
- the fluorescence emission by VEGF was reduced, and it was confirmed that the fluorescence brightness decreased in a concentration-dependent manner.
- the VEGF-administered group leaked out of the blood vessel more than five times as compared to the normal group (CON), whereas the COPH-administered group decreased in a concentration-dependent manner, in particular 5 ⁇ g /
- the ml and 10 ⁇ g / ml concentration groups inhibited fluorescence leakage due to blood retinal barrier damage to the same extent as the normal group.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
Abstract
Description
구분 | 농도(/) | 저해효과(%) | IC50(/) |
COPH(아이비엽 추출물+황련 추출물) | 25 | 35.53±4.48 | 46.05±3.02 |
50 | 43.06±2.82 | ||
70 | 51.08±0.79 | ||
COPH+포도씨1(COPH:포도씨=1:1) | 2.5 | 15.12±1.20 | 7.29±0.10 |
5 | 42.02±1.28 | ||
10 | 65.10±0.36 | ||
COPH+포도씨2(COPH+포도씨=2:1) | 2.5 | 17.09±4.48 | 18.80±0.07 |
5 | 39.15±1.32 | ||
10 | 60.85±0.76 | ||
COPH+포도씨3(COPH+포도씨=3:1) | 2.5 | 18.03±3.91 | 21.27±0.58 |
5 | 39.15±1.32 | ||
10 | 60.85±0.76 | ||
COPH+은행잎(COPH:은행잎=3:1) | 2.5 | 25.09±0.06 | 8.15±0.14 |
50 | 43.98±1.56 | ||
10 | 58.49±1.30 | ||
COPH+갈근1(COPH:갈근=1:1) | 10 | 9.41±0.33 | 47.78±1.24 |
25 | 23.73±1.57 | ||
50 | 52.98±2.06 | ||
COPH+갈근2(COPH:갈근=3:1) | 25 | 22.02±2.13 | 73.53±0.79 |
50 | 33.28±1.86 | ||
75 | 52.13±0.49 | ||
COPH+결명자1(COPH:결명자=1:1) | 10 | 19.54±0.69 | 39.37±0.60 |
25 | 31.18±0.34 | ||
50 | 62.85±0.98 | ||
COPH+결명자2(COPH:결명자=2:1) | 10 | 21.80±2.20 | 46.08±1.22 |
25 | 29.94±1.57 | ||
50 | 54.21±0.93 | ||
COPH+결명자3(COPH:결명자=3:1) | 75 | 48.39±0.39 | 77.79±1.24 |
100 | 56.32±0.23 | ||
125 | 57.76±0.15 | ||
COPH+대황1(COPH:대황=1:1) | 5 | 3.19±1.25 | 21.50±0.23 |
10 | 26.22±0.94 | ||
25 | 57.61±0.76 | ||
COPH+대황2(COPH:대황=2:1) | 10 | 7.57±0.26 | 42.58±1.02 |
25 | 29.50±1.10 | ||
50 | 58.78±1.75 | ||
COPH+빌베리1(COPH:빌베리=1:1) | 10 | 18.37±0.82 | 48.13±1.12 |
25 | 32.85±0.66 | ||
50 | 50.92±0.91 | ||
COPH+빌베리2(COPH:빌베리=2:1) | 10 | 13.62±0.09 | 51.69±0.21 |
25 | 20.08±0.53 | ||
50 | 50.18±0.09 | ||
COPH+빌베리3(COPH:빌베리=3:1) | 10 | 12.26±0.37 | 42.01±0.29 |
25 | 33.49±0.77 | ||
50 | 58.01±0.27 | ||
COPH+빌베리4(COPH:빌베리=1:3) | 5 | 23.85±1.36 | 25.19±0.67 |
10 | 28.66±0.51 | ||
25 | 50.05±0.70 | ||
아미노구아니딘HCl(양성대조군) | 55.5 | 43.92±0.37 | 76.47±4.81 |
74.8 | 50.86±2.17 | ||
92.5 | 54.91±0.75 |
처리한 COPH 농도 (㎍/㎖) | 1.0 | 5.0 | 10.0 |
혈관직경확대 저해율 (%) | 31.16±5.96 | 44.41±4.84 | 49.22±5.79 |
Claims (12)
- 아이비엽과 황련의 혼합 추출물을 유효성분으로 포함하는 당뇨합병증 또는 혈관부종의 예방 또는 치료용 약학적 조성물.
- 제1항에 있어서, 상기 조성물은 아이비엽 추출물과 황련 추출물을 10:1 내지 1:10으로 혼합하여 제조하거나, 또는 아이비엽과 황련을 10:1 내지 1:10으로 혼합한 후 추출하여 제조한 것을 특징으로 하는 약학적 조성물.
- 제1항에 있어서, 상기 조성물은 대황, 갈근, 은행잎, 결명자, 블루베리, 빌베리, 복분자 또는 포도씨 추출물을 추가로 포함하는 것을 특징으로 하는 약학적 조성물.
- 제1항에 있어서, 상기 조성물은 메트포르민(metformin)을 추가로 포함하는 것을 특징으로 하는 약학적 조성물.
- 아이비엽과 황련의 혼합 추출물을 유효성분으로 포함하는 당뇨합병증 또는 혈관부종의 예방 또는 개선용 건강기능식품 조성물.
- 제5항에 있어서, 상기 조성물은 아이비엽 추출물과 황련 추출물을 10:1 내지 1:10으로 혼합하여 제조하거나, 또는 아이비엽과 황련을 10:1 내지 1:10으로 혼합한 후 추출하여 제조한 것을 특징으로 하는 건강기능식품 조성물.
- 제5항에 있어서, 상기 조성물은 대황, 갈근, 은행잎, 결명자, 블루베리, 빌베리, 복분자 또는 포도씨 추출물을 추가로 포함하는 것을 특징으로 하는 건강기능식품 조성물.
- 제1항 또는 제5항에 있어서, 상기 아이비엽 추출물 및 황련 추출물은 각각 아이비엽 및 황련을 물, 메탄올, 에탄올, 부탄올 또는 이들의 혼합용매로 추출하여 수득한 것을 특징으로 하는 조성물.
- 제1항 또는 제5항에 있어서, 상기 추출은 상온 추출, 열수 추출, 냉침 추출, 환류 냉각 추출, 초음파 추출, 초임계 또는 증기 추출인 것을 특징으로 하는 조성물.
- 제1항 또는 제5항에 있어서, 상기 당뇨합병증은 당뇨성 안구질환, 당뇨성 망막병증, 당뇨성 백내장, 당뇨성 신증, 당뇨성 신경병증, 당뇨성 암, 당뇨성 심장병, 당뇨성 골다공증 또는 당뇨성 동맥경화증인 것을 특징으로 하는 조성물.
- 제1항 또는 제5항에 있어서, 상기 혈관부종은, 하지정맥류, 황반부종 또는 황반병반인 것을 특징으로 하는 조성물.
- 제1항 내지 제4항의 조성물 중 어느 한 항의 조성물을 이를 필요로 하는 개체에 투여하는 단계를 포함하는 당뇨합병증 또는 혈관부종의 예방 또는 치료방법.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015552581A JP2016504414A (ja) | 2013-01-10 | 2014-01-10 | 天然抽出物を含む糖尿病合併症若しくは血管浮腫の予防又は治療用の薬学的組成物及び健康機能食品組成物 |
CN201480013313.9A CN105025910A (zh) | 2013-01-10 | 2014-01-10 | 用于预防或治疗糖尿病并发症或血管性水肿的含有天然提取物的药物组合物和功能食品 |
EP14737578.6A EP2944316A4 (en) | 2013-01-10 | 2014-01-10 | PHARMACEUTICAL COMPOSITION AND FUNCTIONAL NUTRITION WITH NATURAL EXTRACTS FOR PREVENTING OR TREATING DIABETIC COMPLICATIONS OR ANGIODEMENTS |
US14/759,471 US9844575B2 (en) | 2013-01-10 | 2014-01-10 | Pharmaceutical composition and functional food comprising natural extracts for preventing or treating diabetic complications or angiodema |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20130003125 | 2013-01-10 | ||
KR10-2013-0003125 | 2013-01-10 | ||
KR10-2013-0050320 | 2013-05-03 | ||
KR1020130050320A KR101498665B1 (ko) | 2013-01-10 | 2013-05-03 | 천연 추출물을 포함하는 당뇨합병증 또는 혈관부종의 예방 또는 치료용 약학적 조성물 및 건강기능식품 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014109587A1 true WO2014109587A1 (ko) | 2014-07-17 |
Family
ID=51738339
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2014/000292 WO2014109587A1 (ko) | 2013-01-10 | 2014-01-10 | 천연 추출물을 포함하는 당뇨합병증 또는 혈관부종의 예방 또는 치료용 약학적 조성물 및 건강기능식품 조성물 |
Country Status (6)
Country | Link |
---|---|
US (1) | US9844575B2 (ko) |
EP (1) | EP2944316A4 (ko) |
JP (1) | JP2016504414A (ko) |
KR (1) | KR101498665B1 (ko) |
CN (1) | CN105025910A (ko) |
WO (1) | WO2014109587A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109498671A (zh) * | 2018-12-27 | 2019-03-22 | 浙江大学 | 一种防治糖尿病肾病的天然产物组合物及应用 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106235333A (zh) * | 2016-08-08 | 2016-12-21 | 徐州工程学院 | 一种用于降低高脂血的保健品添加剂及其制备方法 |
US10493118B2 (en) * | 2016-09-29 | 2019-12-03 | Macau University Of Science And Technology | Triterpenoid obtainable from hedera helix for treatment of neurodegenerative diseases |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR19980033798A (ko) * | 1996-11-01 | 1998-08-05 | 김상조 | 당뇨병 치료용 의약조성물 |
WO2008065457A2 (en) * | 2006-11-29 | 2008-06-05 | Ante Juros | Herbal mixture with fraxinus, achillea and melissa to improve metabolism, boost immunity and help in therapy |
KR20090129936A (ko) * | 2008-06-13 | 2009-12-17 | 안국약품 주식회사 | 혼합 생약 추출물을 함유하는 약학적 조성물 |
KR20100108869A (ko) * | 2009-03-30 | 2010-10-08 | 호서대학교 산학협력단 | 생약재 혼합 추출물을 포함하는 당뇨병 예방 및 치료용 조성물 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002241299A (ja) * | 2001-02-13 | 2002-08-28 | Ichimaru Pharcos Co Ltd | メイラード反応修復剤 |
KR20050089238A (ko) * | 2004-03-04 | 2005-09-08 | 한국 한의학 연구원 | 황련의 알콜 추출물 또는 그로부터 분리된 베르베린을유효성분으로 하는 당뇨합병증의 예방 및 치료용 조성물 |
CN1872138A (zh) * | 2006-04-24 | 2006-12-06 | 北京国丹药物技术开发有限公司 | 一种可用于治疗糖尿病的药用组合物及其制备方法 |
AU2009258384B2 (en) * | 2008-06-13 | 2013-01-10 | Ahn-Gook Pharmaceutical Co., Ltd. | Extract of Coptidis rhizoma and use thereof in treating respiratory disease |
CN101396445A (zh) * | 2008-10-31 | 2009-04-01 | 中山大学 | 黄连总碱在制备糖尿病并发症治疗药物中的应用 |
CN101406576B (zh) * | 2008-11-24 | 2012-03-21 | 浙江省中药研究所有限公司 | 一种治疗糖尿病的中药及制备方法 |
KR101090319B1 (ko) * | 2009-03-27 | 2011-12-07 | 유 선 정 | 당뇨병 예방 및 치료용 약제학적 조성물 |
KR101135957B1 (ko) * | 2009-09-22 | 2012-07-09 | 박철기 | 생약으로부터 얻어진 추출농축액 및 이를 포함하는 당뇨병, 췌장염, 신장염 및 당뇨병성 신부전의 예방과 치료용 건강식품 및 약제학적 조성물 |
CN102240332A (zh) * | 2011-06-17 | 2011-11-16 | 中国中医科学院中药研究所 | 一种药物组合物及其用途 |
-
2013
- 2013-05-03 KR KR1020130050320A patent/KR101498665B1/ko active IP Right Grant
-
2014
- 2014-01-10 US US14/759,471 patent/US9844575B2/en active Active
- 2014-01-10 EP EP14737578.6A patent/EP2944316A4/en not_active Withdrawn
- 2014-01-10 CN CN201480013313.9A patent/CN105025910A/zh active Pending
- 2014-01-10 WO PCT/KR2014/000292 patent/WO2014109587A1/ko active Application Filing
- 2014-01-10 JP JP2015552581A patent/JP2016504414A/ja active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR19980033798A (ko) * | 1996-11-01 | 1998-08-05 | 김상조 | 당뇨병 치료용 의약조성물 |
WO2008065457A2 (en) * | 2006-11-29 | 2008-06-05 | Ante Juros | Herbal mixture with fraxinus, achillea and melissa to improve metabolism, boost immunity and help in therapy |
KR20090129936A (ko) * | 2008-06-13 | 2009-12-17 | 안국약품 주식회사 | 혼합 생약 추출물을 함유하는 약학적 조성물 |
KR20100108869A (ko) * | 2009-03-30 | 2010-10-08 | 호서대학교 산학협력단 | 생약재 혼합 추출물을 포함하는 당뇨병 예방 및 치료용 조성물 |
Non-Patent Citations (5)
Title |
---|
"Diabetes", 2011, KOREA MEDICAL BOOK PUBLISHER, pages: 577 |
IBRAR, M. ET AL.: "Hypoglycemic activity of Hedera helix L. leaves and the possible mechanism of action", PAKISTAN JOURNAL OF BOTANY, vol. 35, no. 5, 2003, pages 805 - 809, XP055269665 * |
See also references of EP2944316A4 * |
SMITH, P. R. ET AL., EUR. J. BIOCHEM., vol. 210, 1992, pages 729 - 739 |
VINSON, J. A. ET AL., J. NUTRITIONAL BIOCHEMISTRY, vol. 7, 1996, pages 559 - 663 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109498671A (zh) * | 2018-12-27 | 2019-03-22 | 浙江大学 | 一种防治糖尿病肾病的天然产物组合物及应用 |
Also Published As
Publication number | Publication date |
---|---|
KR101498665B1 (ko) | 2015-03-05 |
EP2944316A4 (en) | 2016-09-14 |
CN105025910A (zh) | 2015-11-04 |
JP2016504414A (ja) | 2016-02-12 |
EP2944316A1 (en) | 2015-11-18 |
US9844575B2 (en) | 2017-12-19 |
KR20140090920A (ko) | 2014-07-18 |
US20150343005A1 (en) | 2015-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012050396A2 (ko) | 생약 추출물을 포함하는 간암 예방 또는 치료용 약학적 조성물 | |
WO2012134126A2 (en) | Use of compounds isolated from morus bark | |
WO2012124888A2 (en) | Composition comprising the extract of herbal combination for preventing or treating diabetic peripheral neuropathy | |
WO2016032249A1 (ko) | 모새나무 추출물 또는 이의 분획물을 유효성분으로 포함하는 신경염증 또는 퇴행성 뇌신경 질환의 예방 또는 치료용 약학적 조성물 | |
WO2021049864A1 (ko) | 두릅나무 추출물을 함유하는 안구건조증 개선용 조성물 | |
WO2014109587A1 (ko) | 천연 추출물을 포함하는 당뇨합병증 또는 혈관부종의 예방 또는 치료용 약학적 조성물 및 건강기능식품 조성물 | |
WO2012124887A2 (en) | Composition comprising the extract of herbs for preventing or treating neurodegenerative disorders | |
WO2011102690A2 (ko) | 둥근잎유홍초 추출물을 함유하는 당뇨병 치료용 약학적 조성물 | |
WO2016006947A1 (ko) | 환삼덩굴 추출물을 유효성분으로 포함하는 퇴행성 뇌질환의 예방 또는 치료용 조성물 | |
WO2015064975A1 (en) | Compositions comprising a viola herba extract, or an extract of viola herba, persicae semen, cinnamomi ramulus, and glycyrrhiza spp. for the prevention or treatment of lipid-related cardiovascular diseases and obesity | |
WO2017183924A1 (ko) | 단풍나무 잎 추출물을 포함하는 안구건조증의 예방 또는 치료용 조성물 | |
WO2019022482A2 (ko) | 황칠나무 추출물을 유효성분으로 포함하는 섬유화 질환의 예방 또는 치료용 조성물 | |
WO2013012117A1 (en) | Pharmaceutical compositions for preventing or treating inflammatory diseases, comprising phytosterol compound | |
WO2022039421A1 (ko) | 아베마시클립을 유효성분으로 포함하는 퇴행성 뇌질환의 예방 또는 치료용 약학적 조성물 | |
WO2022163971A1 (ko) | 콜린에스터라제 억제제 및 항산화제를 포함하는 뇌질환 치료용 약학적 복합 조성물 | |
WO2020204479A1 (ko) | 포도잎 추출물 및 병풀 추출물을 포함하는 정맥순환 장애 개선용 조성물 | |
WO2015072667A1 (ko) | 퇴행성 뇌신경질환의 예방 또는 치료용 약학적 조성물 | |
WO2019225942A1 (ko) | 견사단백질을 갖는 익힌 누에가공물을 포함하는 기억력 개선용 조성물 또는, 알츠하이머 치매 예방 및 치료용 조성물 | |
WO2016032250A1 (ko) | 채송화 추출물 또는 이의 분획물을 유효성분으로 포함하는 신경염증 또는 퇴행성 뇌신경 질환의 예방 또는 치료용 약학적 조성물 | |
WO2019098568A2 (ko) | 동백나무 추출물을 포함하는 통증의 완화, 예방 또는 치료용 조성물 | |
WO2018117572A1 (ko) | 해삼 추출물을 유효성분으로 하는 브루크막 기능 저하 관련 질병 예방 및 치료용 조성물 | |
WO2023182757A1 (ko) | 뇌졸중의 예방 및 치료용 조성물 | |
WO2022240206A1 (ko) | 오갈피 추출물 및 가르시니아 캄보지아 추출물 또는 이들로부터 분리한 화합물을 유효성분으로 포함하는 간 질환 예방 또는 치료용 조성물 | |
WO2023022390A1 (ko) | 황칠 추출물을 포함하는 눈 손상 방지용 조성물 | |
WO2023085820A2 (ko) | 근육 질환의 예방 또는 치료용 약학적 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201480013313.9 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14737578 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2015552581 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14759471 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014737578 Country of ref document: EP |